On September 4, 2025, IceCure Medical Ltd. announced encouraging findings from a recently published, independently conducted study evaluating the efficacy and safety of ProSense® cryoablation in treating symptomatic abdominal wall endometriosis (AWE). The peer-reviewed study, published in the Journal of Personalized Medicine, was conducted at Nîmes University Hospital in France. AWE is a debilitating condition characterized by cyclic pain and a palpable mass, often occurring after caesarean sections.
The study, which enrolled 14 patients with a total of 23 AWE lesions treated between September 2022 and April 2025, reported that pain scores declined substantially from a median of 8 on a scale of 0-10 to a median of 0 for patients who underwent ProSense® cryoablation procedures. The researchers concluded that percutaneous cryoablation with ProSense® is a safe and effective minimally invasive tool for AWE, offering significant pain relief and excellent cosmetic outcomes.
IceCure's CEO, Eyal Shamir, highlighted that evidence of ProSense®'s efficacy in multiple gynecological indications further supports its commercial potential and momentum. ProSense® is already FDA cleared and approved in the European Union for gynecological indications, positioning the company to address a significant unmet need for women suffering from AWE.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.